“…The results of our search of the literature identified 56 clinical trials investigating the role of patient NGAL level as an early biomarker in the detection of AKI. 8,9,12,14,17,19,112 Neutrophil gelatinase-associated lipocalin has been shown to be an early marker of AKI in a wide spectrum of clinical conditions, 12,[24][25][26][27][28][29][30]66,67,112 including postcardiac catheterization, 31 cardiac surgery, and cardiopulmonary bypass (CPB) 17,19,33,35,45,47,50,51,54,55,57,58,60,62,64,70,71 ; coronary artery disease (CAD) 52,61 ; heart failure 9,52 ; treatment in an intensive care unit (ICU) 38,42,46 ; in trauma patients 8,14,68 ; patients with toxic AKI and CIN 17,31,36,39,60,63 ; CKD 32,53,56,59 ; renal allograft and transplantation 36,44,53 ; post liver transplantation 40,106,110 ; and post heart and lung transplantation. 33,41,74 Moreover, patient NGAL level has been shown to be an early predictor of clinical outcomes in AKI, 12,25,…”